Optimal treatment determination on the basis of haematoma volume and intra-cerebral haemorrhage score in patients with hypertensive putaminal haemorrhages: a retrospective analysis of 310 patients
© Liu et al.; licensee BioMed Central Ltd. 2014
Received: 18 October 2013
Accepted: 30 June 2014
Published: 4 July 2014
Hypertensive putaminal haemorrhage comprises major part of intra-cerebral haemorrhages, with particularly high morbidity and mortality. However, the optimal treatments for these individuals remain controversial.
From June 2010 to August 2013, patients with hypertensive putaminal haemorrhages were treated in the Department of Neurosurgery, West China Hospital. Information regarding the age, signs of cerebral herniation, haematoma volume, intra-ventricular haemorrhage, intra-cerebral haemorrhage score and the treatments of each patient were analyzed retrospectively. The outcome was evaluated by the 30-day mortality rate.
The 30-day mortality rate of the patients with haematomas volume greater than or equal to 30 ml and intra-cerebral haemorrhage scores of 1 or 2 was decreased in the surgical group compared with those in the conservative group (1.92% VS. 21.40%, OR = 0.072, p = 0.028; 15.40% VS. 33.3%, OR = 0.365, p = 0.248, respectively). The mortality rate of the patients with signs of cerebral herniation was not significantly different between the surgical and conservative groups (83.30% VS. 100%; p = 0.529). The intra-cerebral haemorrhage score was significantly associated with the 30-day mortality rate of patients with intra-cerebral haemorrhages (r = -0.798, p < 0.001).
Patients with basal ganglia haematomas volume greater than or equal to 30 ml and intra-cerebral haemorrhage scores of 1 or 2 could benefit from the surgical removal of haematomas. The intra-cerebral haemorrhage score can accurately predict the 30-day mortality rate of patients with hypertensive putaminal haemorrhages.
KeywordsSpontaneous putaminal haemorrhage Intra-cerebral haemorrhage score Surgical indication Intra-cerebral haemorrhage
A spontaneous intra-cerebral haemorrhage (ICH) is a devastating subtype of stroke with an annual incidence of 20–30 per 1,000,000 people . Haematomas within the basal ganglia comprise 60% of all cases with hypertensive ICHs, and these cases have a particularly high morbidity and mortality despite optimized treatments . Dennis MS et al. have reported that the one-year survival rate of patients with these haematomas is only 38%  and that most survivors are disabled . However, the role of surgical and medical therapy in treating putaminal haemorrhage remains controversial. Although the Surgical Trial in Intracerebral haemorrhage (STICH) has shown that there is no significant benefit of early surgery compared with initial conservative treatment in patients with spontaneous ICHs , trials in Japan have shown that early surgery can improve the mortality of patients with spontaneous ICHs . Furthermore, several recent studies have suggested that haematoma clot reduction can limit the brain oedema and local ischaemia, as well as the severity of the neurological deficits that are observed after an ICH . Hence, we believed that a subset of patients with basal ganglia haemorrhages could benefit from the micro-surgical evacuation of haematomas. The ICH score is a simple and reliable clinical grading scale that is used for predicting the early mortality of patients with ICHs . However, there are no existing data regarding treatment selection on the basis of haematoma volume and the ICH score of patients with basal ganglia haemorrhages. Therefore, we conducted a retrospective study to investigate whether the patients with hypertensive putaminal haemorrhages who can benefit from the surgical removal of haematomas on the basis of the haematoma volume and ICH score.
From June 2010 to August 2013, the medical records of patients with hypertensive basal ganglia haemorrhages who were admitted to the Department of Neurosurgery of West China Hospital were retrospectively reviewed. Information on their basic clinical characteristics, treatments and 30-day outcomes after the ictus was collected. The exclusion criteria were as follows: 1) patients with haemorrhages caused by cerebral aneurysms, arteriovenous malformations, brain injuries, cerebral tumours or infarctions, and patients who did not undergo computed tomography cerebral angiography; 2) patients with dysfunctions of coagulation, liver cirrhosis, uremia, heart failure, chronic obstructive pulmonary disease or pregnancy; 3) patients on anticoagulant therapy; 4) patients with haemorrhagic conversion after stoke.
The surgical team included three skilled professors, and the surgical procedure was determined by the neurosurgeon. If the patients with basal ganglia hematoma volume ≥ 30 ml, shift of the midline ≥ 5 mm, compression of the ventricle ≥ 20%, or signs of cerebral herniation, the surgical intervention was mandatory according to the protocol of neurosurgery department. Mortality was assessed 30 days after the ICH ictus. Comatose patients who were discharged voluntarily by their relatives were recorded as deaths. Conscious patients who were discharged were interviewed over telephone 30 days after the ictus. The patients or their relatives signed informed consents after a thorough explanation of the surgical or conservative treatments. The patients signed the informed consent for the publication of their clinical images. The trial was approved by the Biological and Medical Ethics Committee of West China Hospital.
The statistical analysis was performed using SPSS 19.0 software (IBM Corporation, Armonk, NY, USA). The categorical variables are presented as frequencies (percentages) and the continuous variables are presented as means ± standard deviations(SD). For the univariate analysis, the frequencies of the parameters were compared by Chi-square tests for categorical variables. Student’s t-tests were used to compare the continuous variables. The associations of the ICH scores with the 30-day mortality rate of the patients with basal ganglia haemorrhages were assessed with a binary logistic regression. P values less than 0.05 were considered statistically significant.
Baseline clinical characteristics of 310 patients with basal ganglia hemorrhage
(N = 129)
(N = 181)
Age(mean ± SD)
56.59 ± 12.25
58.48 ± 12.78
Hematoma volume(mean ± SD)
38.33 ± 18.35
24.78 ± 16.69
Presense of IVH(n,%)
ICH score(mean ± SD)
1.71 ± 1.26
1.20 ± 1.42
Mortality rate of 30-day
Clinical characteristics of 157 patients with basal ganglia hemorrhage (hematoma volume ≥30 ml)
N = 96
N = 61
Age(mean ± SD)
56.53 ± 12.50
57.95 ± 13.58
ICH score(mean ± SD)
2.04 ± 1.21
2.67 ± 1.21
Hematoma volume(mean ± SD)
45.13 ± 15.99
43.30 ± 15.77
Presence of IVH(n,%)
Signs of hernia (n,%)
30-day mortality rate(n,%)
The 30-day mortality of 157 patients with basal ganglia hematoma (≥30 ml) based on ICH score between surgical and conservative group
(30-day mortality rate)
(30-day mortality rate)
1.92% (N = 51)
21.40% (N = 24)
15.40% (N = 18)
33.30% (N = 9)
37.50% (N = 11)
22.20% (N = 17)
33.30% (N = 13)
54.50% (N = 11)
100.00% (N = 3)
Our study showed that the 30-day mortality rate of patients with moderate basal ganglia haematomas was significantly decreased in the surgical group than that in the conservative group, and these results were similar to those of the other studies [10–13]. This is the first article about combining ICH score and hematoma volume as the indication of surgical removal of hypertensive basal ganglia hematoma. Haematoma volume is a very important factor in the surgical indication of patients with ICHs. In our study, the total 30-day mortality rate of patients with basal ganglia haematomas of 30 ml or more and ICH scores of 1 was significantly lower in the surgical group than in the conservative group. For the patients with ICH scores equal to 2, the 30-day mortality rate was obviously decreased in the surgical group compared with that that in the conservative group. It demonstrated that haematoma clot evacuation could limit the brain oedema and local ischaemia.
The 30-day mortality rate of patients with basal ganglia haematomas volume of ≥ 30 ml and signs of cerebral herniation was up to 90% even the hematoma was evacuated surgically within 24 h after the ictus. In our study, 16 of 18 patients with signs of herniation died within 1 week. The possible explanation was that only removal of haematomas might be insufficient to relieve the increased intra-cranial hypertension. The intra-cranial hypertension would increase again to severe values in few hours because of swelling of brain. Furthermore, the patients with ICH scores equal to 3, the 30-day mortality rate was higher in the surgical group than in the conservative group. Therefore, Treatment should be individualised for patients with basal ganglia haemorrhages. The ICH score was highly associated with the 30-day mortality rate of patients with basal ganglia haemorrhages, which was similar to other studies [14, 15]. Therefore, the ICH score would provide a standard assessment tool, which can be determined rapidly and easily, for treatments selection of patients with hypertensive basal ganglia haemorrhage.
This study demonstrated that surgical intervention would decrease the 30-day mortality rate of patients with hypertensive basal ganglia haematomas of ≥ 30 ml and ICH scores of 1 or 2. But this retrospective study had some limitations. The hematoma removal was through different surgical procedures. Some patients with large haematoma didn’t receive surgical intervention because of economy; However, a subset of patients with basal ganglia hematoma volume of < 30 ml and shift of midline ≥ 5 mm received surgical removal of hematoma. A more definitive conclusion will be achieved from the future trial.
Patients with basal ganglia haematomas volume ≥ 30 ml and ICH scores of 1 or 2 could benefit from micro-surgical interventions. ICH scores should be assessed as part of the surgical indications and routine clinical care.
- ICH score:
Intracerebral hemorrhage score.
This study was supported by grant No.3097382 and No.81172411 from National Natural Science Foundation of China and China Medical Board of New York. We thank Li Qiang, M.D. for correcting the grammar errors of manuscript (the Department of Neurosurgery, West China Hospital, Sichuan University). We thank Katherine Nixon who provided medical writing services on behalf of Enago Crimson Interactive Pvt. Ltd.
- Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hanley DF: Spontaneous intracerebral hemorrhage. N Engl J Med. 2001, 344: 1450-1460. 10.1056/NEJM200105103441907.View ArticlePubMedGoogle Scholar
- Waga S, Miyazaki M, Okada M, Tochio H, Matsushima , Tanaka Y: Hypertensive putaminal hemorrhage: analysis of 182 patients. SurgNeurol. 1986, 26: 159-166.Google Scholar
- Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP: Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993, 24: 796-800. 10.1161/01.STR.24.6.796.View ArticlePubMedGoogle Scholar
- Houguang Z, Yu Z, Ling L, Xu H, Yinghong T, Yuping T, Wei H, Jianzhong X, Qiang D: A prospective controlled study: minimally invasive stereotactic puncture therapy versus conventional craniotomy in the treatment of acute intracerebral hemorrhage. BMC Neurol. 2011, 11: 76-10.1186/1471-2377-11-76.View ArticleGoogle Scholar
- Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw DH: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005, 365: 387-397. 10.1016/S0140-6736(05)17826-X.View ArticlePubMedGoogle Scholar
- Kanaya H, Kuuoda K: Development in neurosurgical approaches to hypertensive intracerebral hemorrhage in Japan. Intracerebral Hematomas. Edited by: Kaufman HH. 1992, New York: Raven Press Ltd.Google Scholar
- Teernstra OPM, Evers SMAA, Lodder J, Leffers P, Franke CL, Blaauw G: Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator – a multicenter randomized controlled trial (SICHPA). Stroke. 2003, 34 (4): 968-974. 10.1161/01.STR.0000063367.52044.40.View ArticlePubMedGoogle Scholar
- Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC: The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001, 32: 891-897. 10.1161/01.STR.32.4.891.View ArticlePubMedGoogle Scholar
- Kothari RU, Brott T, Broderick JP, Barsan WG, Suaer LR, Zuccarello M, Khoury J: The ABCs of measuring intracerebral hemorrhagevolumes. Stroke. 1996, 27: 1304-1305. 10.1161/01.STR.27.8.1304.View ArticlePubMedGoogle Scholar
- Antic B, Rogonovic Z, Tadic R, Raicevic B: Indications for surgical treatment of hypertensive intracerebralsupratentorial hematomas. Vojnosanit Pregl. 1991, 48: 35-39.PubMedGoogle Scholar
- Kaya RA, Türkmenoqlu O, Ziyal IM, Qizhong L, Jiyao J, Yongming Q: The effects on prognosis of surgical treatment of hypertensive putaminal hematomas through transsylviantreansinsular approach. SurgNeurol. 2003, 59: 176-183.Google Scholar
- Jianwei G, Weigiao Z, Xiaohua Z, Qizhong L, Jiyao J, Yongming Q: Our experience of transsylvian-transinsular microsurgical approach to hypertensive putaminal hematomas. J Craniofac Surg. 2009, 20: 1097-1099. 10.1097/SCS.0b013e3181abbf09.View ArticlePubMedGoogle Scholar
- Chen C-H, Lee H-C, Chuang H-C, Chen CC, Lee WY, Huang YI, Chu YT, Cho DY: Transsylvian-transinsular approach for the removal of basal ganglia hemorrhage under a modified intracerebral hemorrhage score. J Craniofac Surg. 2013, 24: 1388-1391. 10.1097/SCS.0b013e318292c302.View ArticlePubMedGoogle Scholar
- Clarke JL, Johnston SC, Farrent M, Bernstein R, Tong D, Hemphill JC: External validation of the ICH score. Neurocrit Care. 2004, 1 (1): 53-60. 10.1385/NCC:1:1:53.View ArticlePubMedGoogle Scholar
- Hemphill JC, Farrent M, Neil TA, Neill TAJ: Prospectivevalidation of the ICHScore for 12-month functional outcome. Neurology. 2009, 73 (14): 1088-1094. 10.1212/WNL.0b013e3181b8b332.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/14/141/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.